FDA Gives Thumbs-Up to Sunovion’s Under-the-Tongue Parkinson’s Drug
The U.S. Food and Drug Administration approved Marlborough, Massachusetts-based Sunovion Pharmaceuticals’ Kynmobi (apomorphine HCl) sublingual film for Parkinson’s disease.
About BioSpace
This author has yet to write their bio.Meanwhile lets just say that we are proud BioSpace contributed a whooping 3627 entries.
Entries by BioSpace
Roche Acquires Stratos Genomics to Expand Nanopore Sequencing Technology
Switzerland’s Roche acquired genetic sequencing company Stratos Genomics for an undisclosed amount.
Following Failure to Sell, Akorn Files for Chapter 11
Two years after Germany’s Fresenius Medical Care walked away from a 2017 $4.3 billion deal to acquire Akorn Pharmaceuticals, the Illinois-based company filed for protection under U.S. bankruptcy laws in an attempt to restructure for a potential sale.
Sorrento Responds to Criticism of COVID-19 Neutralizing Antibodies
In a BioSpace interview, Sorrento Therapeutics executives emphasized the stringent process the company went through in identifying the antibody STI-1499, which demonstrated 100 percent inhibition of SARS-CoV-2 in laboratory tests.
High Dose of JAK Inhibitor Filgotinib Hits the Mark in UC Study
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences Inc. and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
HotSpot Therapeutics Eyes Clinic Following $65 Million Series B
Two years after Boston-based HotSpot Therapeutics launched, the company secured $65 million in Series B funding to advance the development of allosteric therapies that target “regulatory hotspots” in the body into the clinic.
China’s CanSinoBIO Partners with Canada’s Precision NanoSystems on COVID-19 Vaccine
Tianjin, China’s CanSino Biologics entered into a co-development agreement with Vancouver, British Columbia’s Precision NanoSystems for an mRNA lipid nanoparticle vaccine against COVID-19.
Mammoth Strikes Deal with GSK Consumer Healthcare to Develop COVID-19 Test Using CRISPR-Based Platform
Weeks after Mammoth Biosciences announced the company’s CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the Bay Area-based firm struck a deal with GlaxoSmithKline to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.
Ease of Use, Higher Efficacy Drive Lilly’s New Diabetes Treatments
Diabetes and obesity remain a problem, even during a pandemic. Eli Lilly is developing 13 diabetes drugs in Phase I through Phase III trials, with data from various trials planned for release throughout 2020.
Lynparza Becomes Second PARP Inhibitor Approved for Prostate Cancer
The U.S. Food and Drug Administration approved AstraZeneca and Merck’s powerhouse PARP inhibitor Lynparza for prostate cancer only a handful of days after Clovis Oncology’s Rubraca became the first one.